Status:
COMPLETED
Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma
Lead Sponsor:
Meir Medical Center
Conditions:
Non-Hodgkin's Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
In previous studies, the investigators found that in patients with Hodgkin's lymphoma (HL) treated with ABVD (adriamycin, bleomycin, vinblastine and decarbazine) the absence of alopecia may predict fo...
Detailed Description
Aim of the study: To evaluate the association between response to chemotherapy, the degree of myelosuppression and the pharmacokinetics of doxorubicin in non-Hodgkin's lymphoma (NHL) patients. Metho...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Biopsy proven intermediate grade NHL
- No previous chemotherapy
- At least 4 courses of R-CHOP at maximal doses are planned
- An informed consent
Exclusion
- Do not meet all inclusion criteria
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00969462
Start Date
September 1 2009
End Date
December 1 2012
Last Update
July 1 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Departmetn of Medicine. Meir Medical Center
Kfar Saba, Israel, 44281